Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that its
first phase IIa trial of MIV-711 for the treatment of osteoarthritis has been
fully enrolled. In addition, the second planned meeting of the independent Drug
Monitoring Committee (DMC) has taken place, and concluded by again recommending
that the trial should go ahead.

The phase IIa study, known as MIV-711-201, enrolled 244 patients into 3 arms,
each with approximately 80 patients, and is designed to compare MIV-711 dosed at
100mg or 200 mg once daily against placebo. The key objectives are to assess the
effect of six months of treatment with MIV-711 on knee joint clinical pain and
on knee OA, assessed using magnetic resonance imaging, as well as the safety and
tolerability of MIV-711. It is expected that data from the study will available
in the third quarter of 2017.

As part of the study, an independent DMC is periodically scheduled to review the
unblinded safety data from the trial. The DMC’s voting members are two expert
physicians and one biostatistician. The possible recommendations from such a
review, based on the analysis of the accumulated safety data, could be 1) Go
ahead, 2) Go ahead but with modification, 3) Suspend enrollment or 4) Stop
enrollment. Based on the review of the accumulated safety data after the first
100 subjects had completed three months of treatment, the DMC has recommended
that the phase IIa trial of osteoarthritis should go ahead.

“The completion of enrollment into MIV-711-201 is an important milestone in the
continuing development of MIV-711. Furthermore the timely completion of
enrollment into this study demonstrates Medivir’s ability to design and run
complex clinical development projects”, said Dr Richard Bethell, CSO at Medivir.
“On behalf of Medivir, I’d like to thank all the patients involved in MIV-711
-201 for their participation in this important study.”

MIV-711 is being developed as a DMOAD, i.e. a drug to slow or reverse the
progression of the degeneration of joints affected by OA. There are no DMOADs
approved for use currently, and the standard of care for OA patients is based on
analgesics, with the potential for associated side effect risks such as GI
bleeding and opioid dependency, and life style measures. DMOADs for
osteoarthritis therefore represent a very large and attractive market
opportunity. Medivir estimates that the US market alone is greater than USD 6
billion annually for a drug that impacts disease progression, even if its use
was restricted just to patient populations with moderate osteoarthritis in
weight-bearing joints.

Further information on the trial planning and conduct can be found on
www.clinicaltrials.gov with identifier NCT02705625.

For further information, please contact:
Richard Bethell, CSO Medivir AB, mobile +46 (0)72-704 3211
Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580

Medivir is required under the Securities Markets Act to make the information in
this press release public.
The information was submitted for publication at 10.15 CET on 27 October 2016.


About Medivir
Medivir is a research based pharmaceutical company with a research focus on
oncology and infectious diseases. We have a leading competence within protease
inhibitor design and nucleotide/nucleoside science and we are dedicated to
develop innovative pharmaceuticals that meet great unmet medical need. Our
commercial organization provides a portfolio of specialty care pharmaceuticals
on the Nordic market.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.